ALGS Q2 2024 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-84.6% YoY

Gross Profit

$451,00042.5% margin

Operating Income

-$26M-2489.5% margin

Net Income

$5M477.0% margin

EPS (Diluted)

$0.81

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$109M

Total Liabilities

$42M

Stockholders' Equity

$67M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$7M	-84.6%
Gross Profit	$451,000	$7M	-93.5%
Operating Income	-$26M	-$19M	-38.0%
Net Income	$5M	-$19M	+126.9%